Neuralstem is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disease based on transplanting human neural stem cells and the use of small molecule drugs. CUR is in an FDA-approved phase 1 safety clinical trial for amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, and has been awarded orphan status designation by the FDA. For more information visit the company’s Web site at www.neuralstem.com.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research, sales, and trading services. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.

Let us hear your thoughts below: